WASF2 Recombinant Antibody

$25 ug total protein per lane of various lysates (see on figure) probed with WASF2 monoclonal antibody, unconjugated (bsm-61277R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with WASF2 monoclonal antibody, unconjugated (bsm-61277R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

WB
IHC-P
IHC-F
IF(IHC-P)

Reactivity

Human

Overview
Catalog #	bsm-61277r-TR
Product Name	WASF2 Recombinant Antibody
Applications	WB IHC-P IHC-F IF(IHC-P)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human WASF2
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	10163
Swiss Prot	Q9Y6W5
Subcellular location	Cytoplasm, Cell membrane
Synonyms	Wiskott-Aldrich syndrome protein family member 2WASP family protein member 2; Protein WAVE-2; Verprolin homology domain-containing protein 2; WASF2.
Background	Downstream effector molecule involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Promotes formation of actin filaments. Part of the WAVE complex that regulates lamellipodia formation. The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex.
Application Dilution
WB	1:500-2000
IHC-P	IHC-P1:100-200
IHC-F	IHC-F1:100-200
IF(IHC-P)	IFIHC-P1:100-200